Navigation Links
Mitotech’s SkQ1 Improved Visual Acuity in Leber’s Hereditary Optic Neuropathy (LHON) Patients
Date:4/27/2017

Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive results of a clinical study in Leber’s Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads to a sudden and rapid loss of central vision. Mitotech studied efficacy of SkQ1 eye drops in a group of 20 patients carrying 11778, 14484 and 3460 mutations and having experienced the onset of symptoms more than 12 months before enrollment. In the study, patients treated with Mitotech’s SkQ1 –a small molecule engineered to reduce oxidative stress inside mitochondria – demonstrated statistically significant average improvement of visual acuity of 0.3 logMAR over the first 6 months of treatment with even stronger response over the next two years of treatment.

“It is encouraging to see such a rapid onset of action for our drug and its continued effect at advanced stages of the disease,” said Natalia Perekhvatova, CEO of Mitotech S.A. “SkQ1 was designed to counter excess of ROS in mitochondria and these data demonstrated relevancy of our approach for Leber’s Hereditary Optic Neuropathy – a genetic disease causing blindness. This result is extremely valuable for our clinical development of SkQ1 for LHON and potentially for other mitochondrial disorders in the U.S., Europe and other markets.”

The study was conducted in Russia and was designed as an open label study enrolling LHON patients with specific point mutations. Enrolled patients topically administered SkQ1 ophthalmic solution for 30 months TID. Data analysis for 20 patients enrolled more than 12 months after the onset of vision loss demonstrated statistically significant improvement of Best Corrected Visual Acuity (BCVA) after just 6 months of treatment with further sustained improvement of BCVA over the remaining two years of the study. On average, BCVA was improved by 0.3 logMAR after the first 6 months of treatment. Enrolled patients were predominantly male averaging 29 years of age with 1 to 18 years since the onset of vision loss. Mitotech’s study did not have a control group, but it is worth noting that previous studies conducted by other research groups have demonstrated no statistically significant BCVA improvement for LHON patients on placebo treatment.

"The study started in 2013 and took three and a half years from start to finish,” said Elena Karger, Mitotech’s study director “We are excited to see that SkQ1 demonstrated a really unique effect of improving vision acuity in LHON patients with established vision loss. The study also provided valuable long-term safety data for ophthalmic use of SkQ1. We did not observe any notable treatment-related adverse events over the 30-month treatment course. This result also serves as evidence of SkQ1’s ability to reach back of the eye in therapeutic amounts. That was a limited study, but it is a great first step to possible approval of our drug for LHON.”

About Mitotech S.A

Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria targeting cardiolipin peroxidation inhibitors. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases. Mitotech successfully completed Phase 2 clinical study for Dry Eye indication in the U.S. with other indications also approaching clinical stage of development.

Read the full story at http://www.prweb.com/releases/2017/04/prweb14279298.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer
2. Technology and Telemedicine Advancements in Healthcare Boosting Improved Patient Care
3. Study Suggests Improved Method For Pinpointing If Prostate Cancer Will Return - Dr. David Samadi Investigates
4. Interbody-Fusion Outcomes May Be Improved by Use of Invibio's PEEK-OPTIMA™ HA Enhanced Polymer
5. Quadrant Plastics and MediTECH Present Material Technologies Key to Improved Performance and Reduced Production Costs in Medical Device Market at OMTEC 2016
6. New Research Reviews Tests for Improved Mesothelioma Diagnosis, According to Surviving Mesothelioma
7. Shimadzu Introduces New ATHAP Matrix Kits for Improved Characterization of Hydrophobic Peptides and Proteins
8. VWR Continues to Deliver an Improved Web Experience to Customers
9. Sangamo BioSciences Announces Publication Of Improved Method For Efficient Targeted Integration In Hematopoietic Stem Cells And T-cells
10. Discovery Scientific Solutions (DSS) New Website Redesign Provides Improved Functionality to Meet Customers’ Scientific Instrument Needs
11. Understanding Challenging Applications for Improved Metal Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin ... of Clinical Operations. She brings years of expertise in establishing and leading clinical ... foundation as a licensed occupational therapist, through a variety of leadership roles in ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... other leaders of the Maryland Biohealth community in developing and issuing recommendations to ... 3 U.S. BioHealth Innovation Hub by 2023. , The recommendations ...
(Date:5/19/2017)... PA (PRWEB) , ... May 19, 2017 , ... ... its QED Proof-of-Concept Program. Academic researchers with technologies ripe for commercialization, and ... New Jersey and Delaware, are encouraged to submit proposals. QED, now in its ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... its scientific power by providing investigators access to a high-profile scientific advisory ... the scientific advisory board. “We are committed to offering superior services and ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):